Loss of CYP3A7 gene induction by 1,25-dihydroxyvitamin D3 is caused by less binding of VDR to the proximal ER6 in CYP3A7 gene

Biochemical and Biophysical Research Communications
Hirokazu HaraTetsuo Adachi

Abstract

Cytochrome P450 3A4 and 3A7 (CYP3A4 and CYP3A7, respectively) are predominant forms in the human adult and fetal liver, respectively. 1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is known to be a potent inducer of CYP3A4 in human colon carcinoma Caco-2 via vitamin D receptor (VDR). However, whether CYP3A7 is inducible by 1,25(OH)(2)D(3) has not yet been elucidated. In the present study, we examined the effect of 1,25(OH)(2)D(3) on CYP3A7 gene expression in Caco-2 cells, which express CYP3A4 and CYP3A7 mRNAs. 1,25(OH)(2)D(3) hardly induced the expression of CYP3A7 mRNA in contrast to the marked induction of CYP3A4 mRNA. Reporter assay using 5'-franking region CYP3A4 and CYP3A7 genes also revealed that 1,25(OH)(2)D(3) activates CYP3A4 promoter, but not CYP3A7 promoter, which has two mutations in the proximal ER6 site compared with CYP3A4 promoter. In addition, we found that the binding of VDR to the proximal ER6 in CYP3A7 gene was markedly less than that to the proximal ER6 in CYP3A4 gene using gel shift assay. Taken together, the decrease of VDR binding to the proximal ER6 caused by the mutation results in the loss of CYP3A7 gene activation by 1,25(OH)(2)D(3).

References

Dec 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·J K BurmesterH F DeLuca
Oct 1, 1987·The Journal of Clinical Investigation·P B WatkinsP S Guzelian
Aug 14, 1996·Biochemical and Biophysical Research Communications·J GreuetP Maurel
Oct 15, 1998·Proceedings of the National Academy of Sciences of the United States of America·G BertilssonA Berkenstam
Jul 15, 1999·Biochemical and Biophysical Research Communications·J M PascussiM J Vilarem
Apr 10, 2002·The Journal of Biological Chemistry·Oliver BurkLeszek Wojnowski
May 7, 2002·The Journal of Biological Chemistry·Lionel DrocourtMarie-José Vilarem
May 23, 2002·Science·Makoto MakishimaDavid J Mangelsdorf
Jul 20, 2002·Molecular Pharmacology·Bryan GoodwinChristopher Liddle
Jul 31, 2002·Biochemical and Biophysical Research Communications·Hirokazu HaraTetsuo Adachi
Jun 19, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Yoko YasunamiTetsuo Adachi

❮ Previous
Next ❯

Citations

May 19, 2005·Pharmacogenetics and Genomics·Allan B OkeyPatricia A Harper
Mar 7, 2006·Pharmacogenomics·Guang-Ji WangHong-Guang Xie
Mar 19, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·S HarmsenI Meijerman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.